Last reviewed · How we verify

NCT03394703: K-LUCAS

Korean Lung Cancer Screening Project

Status unknown Last updated 9 January 2018
What this trial tests

trial in Lung Cancer in 8,000 participants. Status unknown.

Timeline
10 April 2017
Primary endpoint
31 December 2017
31 December 2018

Quick facts

Lead sponsorNational Cancer Center, Korea
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment8,000
Start date10 April 2017
Primary completion31 December 2017
Estimated completion31 December 2018
Sites1 location across South Korea

Conditions studied

Sponsor

National Cancer Center, Korea

Who can join

Adults 55 to 74, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Lung cancer is by far the leading cause of cancer death and has a lower relative survival rate than other types of cancer because most lung cancers are detected at an advanced stage when they are first diagnosed. Recently, a randomized control trial suggests that low-dose computed tomography (LDCT) enables an early stage detection and it has been increasingly accepted as an efficient screening method for high-risk individuals to reduce lung cancer mortality. In 2011, The National Lung Screening Trial (NLST) in the U.S. has produced results that screening high-risk smoking groups (who have at least 30 pack-year smoking history and currently smoke or have quit within the past 15 years) aged 55 to 74 years with LDCT reduced lung cancer mortality by 20%. Based on the evidence, Korean National Cancer Center has developed and published the guideline of lung cancer screening using LDCT for high-risk populations in 2015. The guideline recommends annual LDCT screening for high-risk smoking groups aged 55 to 74 years, with at least 30 pack-year smoking history and current smokers or past smokers who quit smoking within 15 years. The Korean Lung Cancer Screening project (K-LUCAS), a nationwide, multicenter, prospective study started to evaluate the effectiveness and feasibility of lung cancer screening with LDCT for considering implementation of a national lung cancer screening program in Korea.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Lung Cancer CT Screening and Lung-RADS in a Tuberculosis-endemic Country: The Korean Lung Cancer Screening Project (K-LUCAS).
    Kim H, Kim HY, Goo JM, Kim Y. · · 2020 · cited 42× · PMID 32286195 · DOI 10.1148/radiol.2020192283
  2. Feasibility of implementing a national lung cancer screening program: Interim results from the Korean Lung Cancer Screening Project (K-LUCAS).
    Lee J, Kim Y, Kim HY, Goo JM, et al · · 2021 · cited 36× · PMID 33718017 · DOI 10.21037/tlcr-20-700
  3. External validation and comparison of the Brock model and Lung-RADS for the baseline lung cancer CT screening using data from the Korean Lung Cancer Screening Project.
    Kim H, Kim HY, Goo JM, Kim Y. · · 2021 · cited 8× · PMID 33241512 · DOI 10.1007/s00330-020-07513-1

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

Other National Cancer Center, Korea trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03394703.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing